Physician profile
Peter B Hanson
NPI 1841216603
$326,935.81
in general payments reported to CMS, 2019-2025
38 companies · $788 in 2025
The $788 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $72.58 · 2021: $324K · 2022: $410 · 2023: $322 · 2024: $725 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,834.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Encore Medical, Lp | $323,838.96 | 2021 | |
| Stryker Corporation | $637.57 | 2019-2025 | Mako, Triathlon, Insignia |
| Davol INC. | $341.19 | 2022 | |
| Becton, Dickinson and Company | $211.85 | 2023-2024 | |
| Pacira Therapeutics, INC. | $193.29 | 2019-2021 | |
| Zimmer Biomet Holdings, INC. | $172.03 | 2019-2025 | Avenir |
| Elevate Surgical Co | $171.34 | 2024-2025 | |
| Myoscience INC. | $155.59 | 2019 | |
| Orthalign INC | $150.00 | 2023 | Orthalign Plus |
| Biotissue Holdings INC. | $134.30 | 2021-2024 | |
| Heraeus Medical, LLC. | $124.73 | 2021-2025 | Palacos |
| Smith+Nephew, INC. | $111.39 | 2021-2025 | Katalyst Bipolar Radial Head System, Evos, Panta 2 |
| Bioventus LLC | $106.47 | 2019-2025 | Supartz Fx Sodium Hyaluronate, Xcell |
| Ethicon US, LLC | $88.86 | 2019-2025 | Stratafix, Ethicon, Vistaseal |
| Depuy Synthes Sales INC. | $84.04 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $78.07 | 2023-2025 | Restrata Wound Matrix |
| Argentum Medical | $43.41 | 2021 | |
| Sanofi-Aventis U.S. LLC | $31.53 | 2019-2023 | |
| Guard Medical INC. | $31.06 | 2025 | Npseal |
| Solventum Corporation | $27.36 | 2025 | Prevena |
| Djo, LLC | $24.53 | 2019 | |
| Ermi LLC | $22.67 | 2025 | |
| Pfizer INC. | $22.42 | 2019 | |
| Polynovo North America LLC | $20.85 | 2024 | Novosorb Btm |
| Kerecis Limited | $19.75 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Pacira Pharmaceuticals Incorporated | $19.54 | 2023 | Zilretta, Iovera |
| Mallinckrodt Enterprises LLC | $19.13 | 2019 | |
| Avanos Medical | $17.60 | 2023 | Trivisc Sodium Hyaluronate |
| Medical Device Business Services, INC. | $15.23 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.72 | 2019 | |
| Fidia Pharma USA INC. | $6.33 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$80,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.